Expert Interview
A Preview of VYD2311, Invivyd’s Investigational Monoclonal Antibody for COVID-19 Prevention and Treatment Ahead of Its Phase 3 Data Readout
Ticker(s): IVVD, PFEInstitution: Yale School of Medicine
- Professor of Pediatrics (Emergency Medicine) specializing in pediatric emergency care, disaster preparedness, and prehospital medicine.
- Treats a high volume of pediatric patients annually in emergency settings, including acute illness, trauma, and disaster-related conditions.
- Primary research and clinical focus is on pediatric disaster medicine, emergency medical services (EMS) systems, and improving preparedness, education, and outcomes for children in emergency and public health crises.
How are you currently managing COVID-19 prevention and treatment in high-risk or immunocompromised patients, and what unmet needs remain?
Added By: sara_adminWhat are your expectations for VYD2311 ahead of the Phase 3 data readout, particularly regarding efficacy against circulating variants and durability of protection?
Added By: sara_adminIn which patient populations do you see the greatest potential role for monoclonal antibodies as pre-exposure prophylaxis for COVID-19?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
